NCT06452329 2025-12-04
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
Bristol-Myers Squibb
Completed
Clinical Trials
13 trialsNCT07098104 2025-08-01
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
Completed
NCT06499298 2025-05-31
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
Bristol-Myers Squibb
Completed
NCT03695952 2025-01-28
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Asan Medical Center
Active not recruiting
NCT06504615 2024-12-13
METAGIO
Bristol-Myers Squibb
Recruiting
NCT06361563 2024-04-12
Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada
Bristol-Myers Squibb
Completed
NCT06361576 2024-04-12
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
Bristol-Myers Squibb
Completed
NCT04291755 2024-04-05
Development and Analysis of a Stool Bank for Cancer Patients
Persephone Biosciences
Recruiting
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT06235164 2024-01-31
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Fujian Medical University
Unknown
NCT06196554 2024-01-09
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown
NCT04936399 2022-05-25
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
Bristol-Myers Squibb
Completed
NCT04771715 2021-02-25
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
Unknown